Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

被引：15

作者：

Segal, N. H. ^{[1
]}

Ou, S-H. I. ^{[2
]}

Balmanoukian, A. S. ^{[3
]}

Massarelli, E. ^{[4
]}

Brahmer, J. R. ^{[5
]}

Weiss, J. ^{[6
]}

Schoffski, P. ^{[7
]}

Antonia, S. J. ^{[8
]}

Massard, C. ^{[9
]}

Zandberg, D. P. ^{[10
]}

Maher, C. ^{[1
]}

Khleif, S. ^{[11
,12
]}

Jin, X. ^{[13
]}

Rebelatto, M. ^{[14
]}

Steele, K. ^{[14
]}

Antal, J. ^{[15
]}

Gupta, A. ^{[15
]}

Spreafico, A. ^{[16
,17
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[2] UC Irvine Sch Med, Dept Med, Div Hematol Oncol, Irvine, CA USA

[3] Angeles Clin & Res Inst, Med Oncol, Los Angeles, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA

[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol & Oncol, Chapel Hill, NC USA

[7] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA

[9] Inst Gustave Roussy, Drug Dev Dept, Villejuif, France

[10] Univ Maryland, Med Oncol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[11] Georgia Regents Univ, Ctr Canc, Immune Therapy Program, Augusta, GA USA

[12] Georgia Regents Univ, Ctr Canc, Expt Therapeut, Augusta, GA USA

[13] MedImmune, Biostat, Gaithersburg, MD USA

[14] MedImmune, Pathol, Gaithersburg, MD USA

[15] MedImmune, Clin Dev, Gaithersburg, MD USA

[16] Princess Margaret Canc Ctr, Div Med, Dept Med Oncol, Toronto, ON, Canada

[17] Princess Margaret Canc Ctr, Hematol Drug Dev Program, Toronto, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw376.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

949O

引用

页数：1